Folinic acid pathway modulation

“Folinic acid pathway modulation” is not the name of a specific molecular target but rather describes the pharmacological use of **folinic acid**—also known as leucovorin or calcium folinate—to influence cellular metabolic pathways involving reduced forms of folic acid. Folinic acid does not require activation by dihydrofolate reductase and can bypass blockades caused by antifolate drugs such as methotrexate. Its most prominent clinical use is as an adjunct to fluoropyrimidine-based chemotherapies like 5-fluorouracil (5-FU), where it enhances antitumor activity by stabilizing the ternary complex between thymidylate synthase and FdUMP (the active metabolite of 5-FU), thereby increasing inhibition of DNA synthesis in rapidly dividing tumor cells. It also serves as a “rescue” agent after high-dose methotrexate therapy to reduce toxicity in normal tissues. While “folinic acid pathway modulation” refers broadly to these therapeutic strategies, it does not correspond to a discrete protein or gene product that would be considered a canonical drug target such as an enzyme or receptor.

Other names

Folinic acidLeucovorinCalcium folinateLevoleucovorin (active isomer)FA (abbreviation sometimes used in regimens)

Enhances binding of 5-FU to thymidylate synthase, stabilizing the inhibitory complex and increasing cytotoxicity against cancer cells (“biochemical modulation”).